Figure 2From: Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinoneScatter plot comparing tedizolid and linezolid minimum inhibitory concentration (MIC) values for 674 staphylococcal isolates other than Staphylococcus aureus. Dashed lines represent the US Food and Drug Administration approved S. aureus breakpoints for tedizolid generalized for all staphylococci (≤0.5 μg/ml [susceptible], 1 μg/ml [intermediate], and ≥2 μg/ml [resistant]) and the Clinical and Laboratory Standards Institute approved breakpoints for linezolid (≤4 μg/ml [susceptible] and ≥8 μg/ml [resistant]). These isolates are primarily from coagulase-negative staphylococcal species (eg, S. epidermidis, S. haemolyticus, S. lugdunensis), though some isolates are from coagulase-positive staphylococcal species other than S. aureus.Back to article page